Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer

    Research output: Contribution to journalArticlepeer-review

    20 Citations (Scopus)


    AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease progression during GEMbased chemotherapy were enrolled. All patients were administered FOLFIRINOX with reduced irinotecan and oxaliplatin (RIO; irinotecan 120 mg/m2 and oxaliplatin 60 mg/m2), which was set according to the phase II study of FOLFIRINOX. The objective response rate (ORR), disease control rate (DCR), progressionfree survival (PFS), overall survival (OS), adverse events were evaluated. Additionally, changes in quality of life (QoL) were assessed using a questionnaire on QoL. RESULTS Between August 2015 and May 2016, a total of 48 patients were enrolled. The median follow-up time was 259 d with a median of 8.5 cycles. The ORR and DCR were 18.8% and 62.5%, respectively, including one patient who showed complete remission. The median PFS was 5.8 mo [95% confidence interval (CI): 3.7-7.9] and median OS was 9.0 mo (95%CI: 6.4-11.6). Neutropenia (64.6%) was the most common grade 3-4 adverse event, followed by febrile neutropenia (16.7%). Although 14.6% of patients experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. In the QoL analysis, the global health status score before treatment was not different from the score at the last visit after treatment (45.43 ± 22.88 vs 48.66 ± 24.14, P = 0.548). CONCLUSION FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities.

    Original languageEnglish
    Pages (from-to)505-515
    Number of pages11
    JournalWorld Journal of Gastrointestinal Oncology
    Issue number12
    Publication statusPublished - 2018 Dec 1


    • Chemotherapy
    • Clinical Trial
    • Gemcitabine refractory
    • Pancreatic cancer
    • Phase II

    ASJC Scopus subject areas

    • Oncology
    • Gastroenterology


    Dive into the research topics of 'Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer'. Together they form a unique fingerprint.

    Cite this